Login / Signup

A patent review of SHP2 allosteric inhibitors (2018-present).

Alessia PetrocchiAlina Ciammaichella
Published in: Expert opinion on therapeutic patents (2024)
Multiple potent allosteric SHP2 inhibitors have been discovered, disclosed, and tested in a variety of preclinical cancer models with strong evidence of efficacy. Fifteen compounds are currently in clinical development, but none of them have been approved for marketing. Until now, long-term benefit of SHP2 inhibitors as monotherapy agents have not been demonstrated due to acquired mechanisms of resistance and/or lack of efficacy. However, combination therapies with a variety of agents, such as MEK, BRAF, EGFR, RAS-G12C and PDL-1 inhibitors, have high potential and are currently an extensive area of investigation.
Keyphrases
  • small molecule
  • small cell lung cancer
  • randomized controlled trial
  • tyrosine kinase
  • epidermal growth factor receptor
  • bone marrow
  • cell proliferation
  • open label
  • combination therapy
  • anti inflammatory